Introduction The coagulopathy of cirrhosis is complex, placing patients at risk for both
bleeding and thrombosis. Direct oral anticoagulants (DOAC s) have equivalent or superior …

Abstract Background and Aims Direct oral anticoagulants (DOAC) are important new
anticoagulant therapies that are not well studied in patients with chronic liver disease. The …

Introduction Anticoagulant treatment in patients with liver cirrhosis is challenging. The aim of
this systematic review was to evaluate clinical outcomes of direct oral anticoagulant (DOAC) …

The introduction of Direct Oral Anticoagulants (DOACs) to the pharmaceutical market
provided patients and clinicians with novel convenient and safe options of anticoagulation …

Opinion statement The risk of thrombosis in patients with chronic liver disease is
increasingly recognized. As patients with cirrhosis develop indications for anticoagulation …

Background & Aims Studies of the effects of direct oral anticoagulants (DOACs) in patients
with cirrhosis have been limited by their small sample size, inclusion of patients with well …

Abstract Background Direct oral anticoagulants (DOACs) are recommended for stroke
prevention in patients with atrial fibrillation (AF) or for treatment of deep vein thrombosis …

Objective: To review the use of direct oral anticoagulants (DOACs) in patients with chronic
liver disease (CLD). Data Sources: A MEDLINE literature search was performed from 1964 …

Direct-acting oral anticoagulants (DOACs) have provided benefit in patients requiring
anticoagulation for certain diseases by decreasing the burden of subcutaneous injections …

Background A complication of chronic liver disease (CLD) is the abnormality of coagulation.
In clinical practice, this increased risk of bleeding has not been identified as a protective …